07.26.21
Ingredients by Nature (IBN), a nutraceutical ingredients manufacturer and supplier, announced the acquisition of the Sytrinol brand, including all of its marketing assets. IBN, widely-recognized for its expertise in citrus ingredients, purchased Sytrinol as a brand well-fitted for the company’s portfolio.
IBN knows the formulation of the ingredient intimately, having manufactured the ingredient for several years prior to the acquisition – this includes years of experience manufacturing the citrus-derived polymethoxylated flavones (PMFs), a key ingredient in Sytrinol’s blend of citrus and palm fruit extracts.
Sytrinol supplementation is associated with cardiovascular health benefits, including healthy total cholesterol and LDL cholesterol levels with an improvement in LDL:HDL ratio, and is also associated with healthy triglyceride levels. Studies have shown that this ingredient can be efficacious in as little as 4 weeks. A randomized, double-blind, placebo-controlled study found that Sytrinol supplementation correlated with a 27% reduction in cholesterol levels, a 25% reduction in LDL cholesterol levels, and a 31% reduction in triglyceride levels.
“Having worked with Sytrinol formulation for a long time, we couldn’t be happier to have this brand underneath our umbrella of citrus-derived ingredients,” Rob Brewster, president of IBN, said. “The science speaks for itself that this is among the best available ingredients for heart health, and we look forward to discovering additional ways to innovate with Sytrinol to bring it to an expanded consumer base.”
With full control of the formulation, IBN plans to explore the combination of its clinically-backed lemon flavonoid branded ingredient, Eriomin, with Sytrinol. Eriomin, which was launched in 2019, confers health benefits which target prediabetes management, as it is linked to improvements in insulin resistance, pro-inflammatory cytokine production, and oxidative stress. Sytrinol’s benefit on blood lipids, IBN said, could make it an ideal candidate in a prediabetes management/cardiovascular support supplement, as excessive blood glucose has been linked to the unhealthy cholesterol and triglyceride levels which Sytrinol targets.
IBN knows the formulation of the ingredient intimately, having manufactured the ingredient for several years prior to the acquisition – this includes years of experience manufacturing the citrus-derived polymethoxylated flavones (PMFs), a key ingredient in Sytrinol’s blend of citrus and palm fruit extracts.
Sytrinol supplementation is associated with cardiovascular health benefits, including healthy total cholesterol and LDL cholesterol levels with an improvement in LDL:HDL ratio, and is also associated with healthy triglyceride levels. Studies have shown that this ingredient can be efficacious in as little as 4 weeks. A randomized, double-blind, placebo-controlled study found that Sytrinol supplementation correlated with a 27% reduction in cholesterol levels, a 25% reduction in LDL cholesterol levels, and a 31% reduction in triglyceride levels.
“Having worked with Sytrinol formulation for a long time, we couldn’t be happier to have this brand underneath our umbrella of citrus-derived ingredients,” Rob Brewster, president of IBN, said. “The science speaks for itself that this is among the best available ingredients for heart health, and we look forward to discovering additional ways to innovate with Sytrinol to bring it to an expanded consumer base.”
With full control of the formulation, IBN plans to explore the combination of its clinically-backed lemon flavonoid branded ingredient, Eriomin, with Sytrinol. Eriomin, which was launched in 2019, confers health benefits which target prediabetes management, as it is linked to improvements in insulin resistance, pro-inflammatory cytokine production, and oxidative stress. Sytrinol’s benefit on blood lipids, IBN said, could make it an ideal candidate in a prediabetes management/cardiovascular support supplement, as excessive blood glucose has been linked to the unhealthy cholesterol and triglyceride levels which Sytrinol targets.
